Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cavan Disease - Overview
Cavan Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Cavan Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cavan Disease - Companies Involved in Therapeutics Development
Aspa Therapeutics Inc
Orphan Star Therapeutics LLC
Cavan Disease - Drug Profiles
BBP-812 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Target Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombint Aspartoacylase Replacement for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy to Activate Aspartoacylase for Cavan Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cavan Disease - Dormant Projects
Cavan Disease - Discontinued Products
Cavan Disease - Product Development Milestones
Featured News & Press Releases
Nov 03, 2021: BridgeBio Pharma announces dosing of first patient in phase 1/2 trial of investigatiol gene therapy for Cavan disease
Oct 22, 2019: BridgeBio Pharma presents on its Central Nervous drug candidate BBP-812 at the European Society of Gene and Cell Therapy Conference
Nov 09, 2017: New gene therapy developed with UNSW researchers targets brain disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Canavan Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Canavan Disease, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Canavan Disease - Pipeline by Aspa Therapeutics Inc, 2021
Canavan Disease - Pipeline by Orphan Star Therapeutics LLC, 2021
Canavan Disease - Dormant Projects, 2021
Canavan Disease - Discontinued Products, 2021